© 2017 Evestra, Inc.

2012

 

November, 30

Evestra closes private offering raising $2.5 million

Evestra announced today that it has closed a private offering raising $2.5 million. Many of the investors who invested in this round have invested in the two previous private financing rounds.

Dr. Shaked, Evestra's CEO commented "We are grateful to our investors for their continuing support in our efforts. These additional funds would enable the Company to further develop its products

October, 18

Evestra signs second R&D collaboration with RCPE, Graz to develop proprietary vaginal drug delivery technology

Evestra announced today that it has signed a second R&D collaboration agreement with The Research Center of Pharmaceutical Engineering (RCPE) located in Graz, Austria, to develop proprietary vaginal drug delivery technology.

July, 23

Evestra out-licenses marketing rights for near-term product for Russia and CIS territories

Evestra announced today that it signed a third corporate partnership with a European company. Under this agreement, Evestra has licensed marketing rights to one of its near-term products for Russian and CIS territories.  In accordance with the terms of the agreement, Evestra received payment on signing of the Agreement and will be entitled to future milestone payments as well as royalties on sales of the product.

July, 17

Evestra's second US patent issued

Evestra announced today the issuing of its second US patent. This patent (8,222,237) describes the synthesis and properties of novel progestin compounds. Dr. Klaus Nickisch, Evestra's CSO, commented, "This new patent further demonstrates the innovative nature of Evestra's research in the hormonal steroid area”

June, 7

Evestra out-licenses rest-of-the-world (ROW) marketing rights for near-term product

Evestra announced today that it has signed a second corporate partnership with a European company.  Under this agreement, Evestra has licensed the marketing rights to one of its near-term products for rest-of-the-world (ROW) territories.  In accordance with the terms of the agreement, Evestra received payment on signing of the Agreement and will be entitled to future milestone payments as well as royalties on sales of the licensed product.

May, 30

Evestra receives a new contract from NIH to manufacture cGMP grade hormonal steroid

Evestra announced today that it has received a $105,000 contract from the NIH for the manufacturing of cGMP grade Levonorgestrel Butyrate. This material’s intended use is for the development of a fertility control agent for a number of female and male contraceptives products, including a long-acting contraceptive.

May, 14

Evestra out-licenses European marketing rights for near-term product

Evestra announced today that it has signed a corporate partnership agreement with a European pharmaceutical company. Under this agreement, Evestra has licensed the European marketing rights to one of its near-term products. In accordance with the terms of the agreement, Evestra received up-front payment on signing of the Agreement and will be entitled to future milestone payments as well as royalties on sales of the product.

Ze'ev Shaked, Ph.D., Evestra's CEO stated "This corporate partnership, being the first partnership executed by the Company, validates Evestra's business and product portfolio strategy and provides an important stepping stone to the continuing value creation".

Klaus Nickisch, Ph.D., Evestra's CSO added, "This partnership will enhance Evestra's product development and R&D capabilities in general"